Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug combo study pulled before starting

NCT ID NCT06901349

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to test two drugs, bimagrumab and tirzepatide, alone or together, for helping adults with obesity or overweight and type 2 diabetes lose weight. It was planned for about 13 months but was withdrawn before enrolling any participants. The main goal was to see how much body weight changed from the start.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Started

May 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have type 2 diabetes * Have a BMI of ≥27 kilograms per square meter (kg/m2) * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) Exclusion Criteria: * Have a prior or planned surgical treatment for obesity, * Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma * Have poorly controlled hypertension * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure * Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes * Have ongoing or a history of bradyarrhythmias other than sinus bradycardia * Have renal impairment * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease * Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality * Have a history of acute or chronic pancreatitis * Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight platelet-type bleeding disorder 10 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Activian Clinical Research

    Kingwood, Texas, 77339, United States

  • Balanced Life Health Care Solutions/SKYCRNG

    Lawrenceville, Georgia, 30046, United States

  • Bingham Memorial Hospital

    Blackfoot, Idaho, 83221, United States

  • CIPREC

    Buenos Aires, Buenos Aires F.D., C1119ACN, Argentina

  • CIPREC

    Buenos Aires, C1061AAS, Argentina

  • Central States Research

    Tulsa, Oklahoma, 74136, United States

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, L6S 0C6, Canada

  • Centricity Research Pointe-Claire Multispecialty

    Pointe-Claire, Quebec, H9R 4S3, Canada

  • Centro Médico Viamonte

    Buenos Aires, Buenos Aires F.D., C1120AAC, Argentina

  • Charter Research - Lady Lake

    The Villages, Florida, 32162, United States

  • Charter Research - Winter Park

    Orlando, Florida, 32803, United States

  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare

    Jacksonville, Florida, 32256, United States

  • Consultorio de Investigación Clínica EMO SRL

    Buenos Aires, Buenos Aires F.D., C1405BUB, Argentina

  • Deaconess Clinic- Gateway

    Newburgh, Indiana, 47630, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Diex Recherche Quebec

    Québec, G1V 4T3, Canada

  • Diex Recherche Trois-Rivieres

    Trois-Rivières, Quebec, G9A 4P3, Canada

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814, United States

  • Excel Medical Clinical Trials

    Boca Raton, Florida, 33434, United States

  • Family First Medical Center

    Idaho Falls, Idaho, 83404, United States

  • Fukuwa Clinic

    Chuo-ku, Tokyo, 104-0031, Japan

  • Global Health Research Center, Inc.

    Miami Lakes, Florida, 33016, United States

  • Great Lakes Research Group, Inc.

    Bay City, Michigan, 48706, United States

  • Hayashi Diabetes Internal Medicine Clinic

    Chigasaki, Kanagawa, 253-0044, Japan

  • Healthy Brain Clinic

    Long Beach, California, 90804, United States

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Kur Research - Columbia Medical

    Columbia, Maryland, 21045, United States

  • L&C Professional Medical Research Institute

    Miami, Florida, 33144, United States

  • Medical Corporation Heishinkai OCROM Clinic

    Suita-shi, Osaka, 565-0853, Japan

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007, United States

  • Orange County Research Center

    Lake Forest, California, 92630, United States

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Premier Clinical Trial Network

    Hamilton, Ontario, L8L 5G4, Canada

  • Remington-Davis, Inc

    Columbus, Ohio, 43215, United States

  • Richmond Clinical Trials

    Richmond, British Columbia, V6V 2L1, Canada

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Shonan Takai Clinic

    Kamakura, Kanagawa, 247-0055, Japan

  • Takai Internal Medicine Clinic

    Kamakura-shi, Kanagawa, 247-0056, Japan

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang Shi, Henan, 471003, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150001, China

  • The Institute of Medical Science, Asahi Life Foundation

    Chuo-ku, Tokyo, 103-0002, Japan

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011, China

  • Tokuyama Clinic

    Mihama-ku,Chiba City, Chiba, 261-0004, Japan

  • Tokyo-Eki Center-building Clinic

    Chuo-ku, Tokyo, 103-0027, Japan

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina, 27514, United States

  • Valley Clinical Trials, Inc.

    Northridge, California, 91325, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Your Research Network

    Niagara Falls, Ontario, L2H 1H5, Canada

  • Yuma Clinical Trials

    Yuma, Arizona, 85364, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.